English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background Empiric antibiotic treatment of serious and healthcare-associated pneumonia (PNA) often includes coverage of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (PSA). Recent publications suggest that patients treated with the combination of vancomycin (V) and piperacillin–tazobactam (PT) have a greater risk of acute kidney injury (AKI) than those treated with V alone, or V in combination with another β-lactam, such as cefepime (C). There is a paucity of data regarding the risk of AKI in other regimens that provide MRSA and PSA coverage, such as linezolid (L)-PT or LC. We examined the incidence of nephrotoxicity in patients who received combination antibiotic therapy for PNA. Methods A retrospective cohort analysis of eligible adult patients (≥18 years) admitted from July 1, 2014 to June 30, 2017 who received ≥48 hours of combination therapy was conducted. Patients were excluded if their baseline serum creatinine was ≥1.4 mg/dL, on renal replacement therapy, or if diagnosed with cystic fibrosis. The primary outcome was incidence of AKI as defined by RIFLE criteria. Comparisons between the groups were analyzed by chi-squared test. To identify variables associated with AKI in a multivariable analysis, a repeated measures, mixed-effects logistic regression was utilized. Results There were 185 patient encounters included in the analysis. RIFLE-defined AKI occurred in treatment groups as follows: VPT 31/98 (31.6%); VC 5/50 (10.0%); LPT 4/12 (33.3%); and LC 4/25 (16.0%). There was a significant difference in rates of AKI among the four groups (P = 0.019). In pooled analyses, no difference was identified between patients receiving V or L (P = 0.73); however, patients who received PT had a higher incidence of AKI compared with those that received C (P = 0.002). In logistic regression analyses, independent predictors of AKI were receipt of PT vs. C (odds ratio [OR] 3.2, 95% confidence interval [CI] 1.3–8.0) and SOFA score ≥9 (OR, 4.5; 95% CI 1.6–12.7). Conclusion No differences in AKI incidence were found between patients receiving vancomycin or linezolid; however, patients receiving piperacillin–tazobactam and those with SOFA scores ≥9 had a higher rate of AKI. Disclosures All authors: No reported disclosures.

open forum infectious diseases

1883. Acute Kidney Injury in Patients With Pneumonia on Concomitant Anti-Methicillin-Resistant <i>Staphylococcus aureus</i> and Anti-Pseudomonal β-Lactam Therapy

1883. Acute Kidney Injury in Patients With Pneumonia on Concomitant Anti-Methicillin-Resistant Staphylococcus aureus and Anti-Pseudomonal β-Lactam Therapy